


Genprex, Inc. (GNPX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001595248

Genprex, Inc. GNPX; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$10.2M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, late filer, thin data, degenerate inputs not computable: distress, fortress balance sheet	
Inputs computable	5 of 14	
Graded from	filings received through Mar 30, 2026 193 days before the rescans; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$2.75 2026-10-08; market equity \$2.3M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 34.6						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(12.9%)	(6.6%)	34.6	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 68.5						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(57.35)	(0.31)	89.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		3.84x	2.96x	47.0	839	2025-12-31
Growth and financing, sleeve percentile 93.8						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(26.0%)	2.1%	90.0	704	2025-12-31
Net share issuance, one year		1,772.4%	2.5%	97.6	634	2026-03-27

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 1772.4%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(98.0%)	8.0%	0
Distance from 52-week high	(99.7%)	(31.4%)	0
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(781.7%)	(1.0%)	1
Book value to price	6.56	0.28	100
Sales to price	0.00	0.31	0
Composite equity issuance, five years	672.6%	20.3%	99
Relative strength against the sector, log excess return	(4.13)	(0.14)	0

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$15.2M
Operating cash flow, four quarters	-\$15.6M
Months of runway	11.7
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$288,868

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$16.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$15.3M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
3	assets	us-gaap:Assets	\$10.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
4	assets	us-gaap:Assets	\$4.1M	2024-12-31	2026-03-30	10-K	0001437749-26-010346
5	current assets	us-gaap:AssetsCurrent	\$8.4M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
6	current liabilities	us-gaap:LiabilitiesCurrent	\$2.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$171.0M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
8	operating income	us-gaap:OperatingIncomeLoss	-\$15.5M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
9	book equity	us-gaap:StockholdersEquity	\$8.0M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
10	liabilities	us-gaap:Liabilities	\$2.2M	2025-12-31	2026-03-30	10-K	0001437749-26-010346
11	operating income	us-gaap:OperatingIncomeLoss	-\$12.4M	2018-12-31	2020-03-30	10-K	0001437749-20-006522
12	interest expense	us-gaap:InterestExpense	\$37,982	2018-12-31	2020-03-30	10-K	0001437749-20-006522
13	revenue	us-gaap:Revenues	\$0	2024-12-31	2025-04-01	10-K	0001437749-25-010311
14	revenue	us-gaap:Revenues	\$0	2023-12-31	2025-04-01	10-K	0001437749-25-010311
15	revenue	us-gaap:Revenues	\$0	2022-12-31	2024-04-01	10-K	0001437749-24-010426
16	revenue	us-gaap:Revenues	\$0	2021-12-31	2023-03-31	10-K	0001437749-23-008847
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$17.6M	2022-12-31	2024-04-01	10-K	0001437749-24-010426
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2022-12-31	2023-03-31	10-K	0001437749-23-008847
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$14.3M	2021-12-31	2023-03-31	10-K	0001437749-23-008847
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$31,700	2021-12-31	2023-03-31	10-K	0001437749-23-008847
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$13.9M	2020-12-31	2022-03-30	10-K	0001437749-22-007680
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$17,564	2020-12-31	2022-03-30	10-K	0001437749-22-007680
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$6.9M	2019-12-31	2021-03-26	10-K	0001437749-21-007317

24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$33,370	2019-12-31	2021-03-26	10-K	0001437749-21-007317
25	assets	us-gaap:Assets	\$10.7M	2023-12-31	2025-04-01	10-K	0001437749-25-010311
26	assets	us-gaap:Assets	\$25.1M	2022-12-31	2024-04-01	10-K	0001437749-24-010426
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,044,856	2026-03-27	2026-03-30	10-K	0001437749-26-010346
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,152,848	2025-03-28	2025-04-01	10-K	0001437749-25-010311